$CCEL
CRYO CELL INTERNATIONAL INC

2024 Q4 Form 10-Q Financial Statement

#000095017024114762 Filed on October 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $8.067M
YoY Change 2.5%
Cost Of Revenue $2.126M
YoY Change -1.41%
Gross Profit $5.941M
YoY Change 3.98%
Gross Profit Margin 73.65%
Selling, General & Admin $4.150M
YoY Change 9.07%
% of Gross Profit 69.85%
Research & Development $193.9K
YoY Change -43.65%
% of Gross Profit 3.26%
Depreciation & Amortization $246.6K
YoY Change -27.23%
% of Gross Profit 4.15%
Operating Expenses $4.344M
YoY Change 4.7%
Operating Profit $1.390M
YoY Change 19.71%
Interest Expense $533.5K
YoY Change 13.59%
% of Operating Profit 38.38%
Other Income/Expense, Net -$10.03K
YoY Change -89.27%
Pretax Income $1.380M
YoY Change 29.25%
Income Tax $328.2K
% Of Pretax Income 23.78%
Net Earnings $1.052M
YoY Change 54.53%
Net Earnings / Revenue 13.04%
Basic Earnings Per Share $0.13
Diluted Earnings Per Share $0.13
COMMON SHARES
Basic Shares Outstanding 8.062M 8.062M
Diluted Shares Outstanding 8.174M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.127M
YoY Change 76.14%
Cash & Equivalents $561.0K $197.4K
Short-Term Investments $1.929M
Other Short-Term Assets $454.6K $416.5K
YoY Change 16.58% -7.58%
Inventory $657.7K $731.4K
Prepaid Expenses $637.1K $512.5K
Receivables $7.309M $6.874M
Other Receivables $0.00
Total Short-Term Assets $12.55M $10.66M
YoY Change 32.81% 7.29%
LONG-TERM ASSETS
Property, Plant & Equipment $21.89M $22.12M
YoY Change 4.27% 17.42%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $921.3K $938.2K
YoY Change -6.86% -32.55%
Long-Term Investments
YoY Change
Other Assets $30.23M $30.16M
YoY Change -1.76% -26.49%
Total Long-Term Assets $52.12M $52.27M
YoY Change 0.69% -12.67%
TOTAL ASSETS
Total Short-Term Assets $12.55M $10.66M
Total Long-Term Assets $52.12M $52.27M
Total Assets $64.68M $62.93M
YoY Change 5.65% -9.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.882M $2.001M
YoY Change -40.71% -28.18%
Accrued Expenses $5.810M $2.681M
YoY Change 12.36% 51.06%
Deferred Revenue $9.789M $9.827M
YoY Change 0.87% 1.34%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $174.6K
YoY Change 7.33%
Total Short-Term Liabilities $21.60M $17.42M
YoY Change 3.53% -6.14%
LONG-TERM LIABILITIES
Long-Term Debt $8.331M
YoY Change -1.63%
Other Long-Term Liabilities $56.29M $55.07M
YoY Change 9.55% 7.46%
Total Long-Term Liabilities $56.29M $55.07M
YoY Change 9.55% 7.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.60M $17.42M
Total Long-Term Liabilities $56.29M $55.07M
Total Liabilities $77.89M $72.49M
YoY Change 7.81% 3.84%
SHAREHOLDERS EQUITY
Retained Earnings -$32.78M -$28.90M
YoY Change 5.19% 44.7%
Common Stock $44.42M $44.19M
YoY Change 1.97% 1.86%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.86M $24.86M
YoY Change 6.08% 6.08%
Treasury Stock Shares
Shareholders Equity -$13.22M -$9.559M
YoY Change
Total Liabilities & Shareholders Equity $64.68M $62.93M
YoY Change 5.65% -9.83%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $1.052M
YoY Change 54.53%
Depreciation, Depletion And Amortization $246.6K
YoY Change -27.23%
Cash From Operating Activities $2.437M
YoY Change 25.48%
INVESTING ACTIVITIES
Capital Expenditures $185.7K
YoY Change -94.36%
Acquisitions
YoY Change
Other Investing Activities -$479.9K
YoY Change 403.83%
Cash From Investing Activities -$665.6K
YoY Change -80.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.043M
YoY Change -326.08%
NET CHANGE
Cash From Operating Activities 2.437M
Cash From Investing Activities -665.6K
Cash From Financing Activities -2.043M
Net Change In Cash -271.8K
YoY Change -49.68%
FREE CASH FLOW
Cash From Operating Activities $2.437M
Capital Expenditures $185.7K
Free Cash Flow $2.252M
YoY Change -266.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40767
dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
749-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
CCEL
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8062159
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
197437
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
406067
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1929458
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
574183
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4172151
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3822300
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6873641
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
512509
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615407
CY2024Q3 us-gaap Inventory Net
InventoryNet
731360
CY2023Q4 us-gaap Inventory Net
InventoryNet
768877
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
122113
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
416479
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
389950
CY2024Q3 us-gaap Assets Current
AssetsCurrent
10660884
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9452837
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22117945
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20996883
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
938221
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
989121
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
5088427
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5260119
CY2024Q3 us-gaap Goodwill
Goodwill
1941411
CY2023Q4 us-gaap Goodwill
Goodwill
1941411
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
896790
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
798046
CY2023Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
746493
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30155644
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30771050
CY2024Q3 us-gaap Assets
Assets
62934473
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2000551
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3174584
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2680573
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5170809
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
174587
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2222728
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1222728
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383891
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q3 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
133333
CY2023Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1200000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9826910
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17422573
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20864001
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45198139
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
48055
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
44226
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
8330630
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
619032
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
55070856
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51388001
CY2024Q3 us-gaap Liabilities
Liabilities
72493429
CY2023Q4 us-gaap Liabilities
Liabilities
72252002
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849619
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8062159
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8286785
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
148496
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
148492
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
44043576
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43411143
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
24855556
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
23431685
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28895472
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31159182
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-9558956
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62934473
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61220770
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8066715
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7869875
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23961761
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23466980
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2125846
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2156187
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6311064
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6366737
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4149785
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3804564
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12510787
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11722435
CY2024Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
12702
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
122671
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3829
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-65154
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
193933
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
344132
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
937907
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
727648
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
194559
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
281277
us-gaap Depreciation And Amortization
DepreciationAndAmortization
287543
us-gaap Depreciation And Amortization
DepreciationAndAmortization
843201
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
6676825
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
6708831
us-gaap Costs And Expenses
CostsAndExpenses
20359130
us-gaap Costs And Expenses
CostsAndExpenses
19594867
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1389890
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1161044
us-gaap Operating Income Loss
OperatingIncomeLoss
3602631
us-gaap Operating Income Loss
OperatingIncomeLoss
3872113
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
522458
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
93386
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1056052
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
100082
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
282731
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58757
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
981
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1181
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3436
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
533464
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
469642
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1119196
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1405825
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10025
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-93423
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
43924
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1243550
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1379865
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1067621
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3646555
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2628563
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
328186
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
387060
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1382845
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
960214
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1051679
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
680561
us-gaap Net Income Loss
NetIncomeLoss
2263710
us-gaap Net Income Loss
NetIncomeLoss
1668349
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8061946
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8286555
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8151967
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8358792
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8173535
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8342067
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8241488
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8374939
us-gaap Profit Loss
ProfitLoss
2263710
us-gaap Profit Loss
ProfitLoss
1668349
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
444850
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1063771
ccel Impairment On Investment
ImpairmentOnInvestment
308000
ccel Impairment On Investment
ImpairmentOnInvestment
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3829
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-65154
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1056052
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
100082
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58757
us-gaap Share Based Compensation
ShareBasedCompensation
631435
us-gaap Share Based Compensation
ShareBasedCompensation
641690
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
918488
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
717052
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
15967
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
16259
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
237299
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
236730
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1215889
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1110755
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-102898
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
152450
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-209209
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-227428
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
26529
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
23738
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
51553
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
79574
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-293685
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
550266
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2490236
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1814218
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-175633
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-217671
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4133696
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4076294
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3853917
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5575440
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2395360
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5124056
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
1066667
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
533333
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
101873
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
179306
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1759828
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1082924
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1358732
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
397831
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3761250
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6163176
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1423871
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
799036
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
106428
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
115690
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2200000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1002
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3200000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
950000
ccel Proceeds From Swap Termination
ProceedsFromSwapTermination
228000
ccel Proceeds From Swap Termination
ProceedsFromSwapTermination
0
ccel Payment Of Earnout
PaymentOfEarnout
0
ccel Payment Of Earnout
PaymentOfEarnout
67500
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-301297
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-532226
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-208630
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1119962
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
406067
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
197437
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
583996
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
100932
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
737867
ccel Construction Costs Payable
ConstructionCostsPayable
-880348
ccel Construction Costs Payable
ConstructionCostsPayable
363225
ccel Duke License Agreement Payable
DukeLicenseAgreementPayable
0
ccel Duke License Agreement Payable
DukeLicenseAgreementPayable
266667
us-gaap Interest Paid Net
InterestPaidNet
1482909
us-gaap Interest Paid Net
InterestPaidNet
1363934
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2385096
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1504647
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-10741178
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1002
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
145941
CY2024Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
16400
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1051679
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-9558956
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1002
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
631435
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1423871
us-gaap Net Income Loss
NetIncomeLoss
2263710
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-9558956
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2864
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
172099
CY2023Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
7584
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
680561
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-16163
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2864
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
641690
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
799036
us-gaap Net Income Loss
NetIncomeLoss
1668349
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-16163
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
55025049
CY2024Q3 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9826910
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2024Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
9813
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
35306
CY2023Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10061
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
31451
CY2024Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
28876
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
90545
CY2023Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
30185
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
85133
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
757558
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6873641
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9826910
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45198139
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q3 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
90545
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
28682
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
757558
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
31775756
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
31478355
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6873641
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50891353
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
16303050
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
12169354
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
55025049
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
85133
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
25109
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
675652
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
31533062
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
31139359
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6437644
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
20676740
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
16600446
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
49662680
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2024Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
631435
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
641690
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
145941
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
172099
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
282731
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58757
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
228000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at August 31, 2024 and November 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8066715
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7869875
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2125846
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2156187
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1389890
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1161044
CY2024Q3 us-gaap Interest Expense
InterestExpense
533464
CY2023Q3 us-gaap Interest Expense
InterestExpense
469642
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23961761
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23466980
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6311064
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6366737
us-gaap Operating Income Loss
OperatingIncomeLoss
3602631
us-gaap Operating Income Loss
OperatingIncomeLoss
3872113
us-gaap Interest Expense
InterestExpense
1119196
us-gaap Interest Expense
InterestExpense
1405825
CY2024Q3 us-gaap Assets
Assets
62934473
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q3 ccel Inventory Collection Kits
InventoryCollectionKits
62873
CY2023Q4 ccel Inventory Collection Kits
InventoryCollectionKits
47739
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2024Q3 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5819787
CY2023Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
6028996
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
938221
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
989121
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
51000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
72000
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
228000
CY2024Q3 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.5
ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
8505217
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
174587
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
8330630
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
8505217
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
260055
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
307221
CY2023Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
206034
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
623577
CY2024Q3 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
409307
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1051679
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
680561
us-gaap Net Income Loss
NetIncomeLoss
2263710
us-gaap Net Income Loss
NetIncomeLoss
1668349
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8061946
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8286555
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8151967
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8358792
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
111589
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
55512
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
89521
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16147
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8173535
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8342067
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8241488
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8374939
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
503278
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y10M17D
CY2024Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.15
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
377568
CY2024Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.49
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
114193
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
103000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
91483
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
125710
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.97
CY2011Q4 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6787460
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6562461
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
896790
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383891
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
619032
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1002923
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1077624
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
89890
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
490310
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
490982
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38247
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
106506
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1002923
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M29D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
88321
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
76690
us-gaap Operating Lease Payments
OperatingLeasePayments
266418
us-gaap Operating Lease Payments
OperatingLeasePayments
254003
CY2023Q4 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
13108064
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-114762-index-headers.html Edgar Link pending
0000950170-24-114762-index.html Edgar Link pending
0000950170-24-114762.txt Edgar Link pending
0000950170-24-114762-xbrl.zip Edgar Link pending
ccel-20240831.htm Edgar Link pending
ccel-20240831.xsd Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
ccel-20240831_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending